Study 7 of 22Dulaglutide literatureThe lancet. Diabetes & endocrinologyTop journal2026
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
Not reported in abstract.
Where it sits
this study against the rest of the dulaglutide corpus2
Preclinical · this one
13
Observational
0
Open-label
3
Randomised
4
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Dulaglutide corpus
DPostmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.Diabetes, obesity & metabolism · 2026 · 243,114 GLP-1 primary-suspect case-product records within 8,995,547 background reports.reviewBTarget Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.Diabetes care · 2026 · sHR for mortality on dialysis 0.82 (95% CI 0.70-0.97; 1-year cumulative incidence 11% vs. 13%)HumanBImpact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.Digestive diseases and sciences · 2026 · 8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.HumanBPrescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2024 · n=2033 · GLP-1RA initiation inversely associated with antidepressants (aSR: 0.85; 95% CI: 0.76-0.94)HumanAEfficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).Diabetes, obesity & metabolism · 2026 · n=573 · ETD for HbA1c reduction: -0.74%; CI95: -0.90, -0.59HumanBProjecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.Diabetes, obesity & metabolism · 2026 · 0.16 QALYs gained with icodec versus glargine U100 and degludec.—